表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）患者脑转移的治疗：EGFR酪氨酸激酶抑制剂的作用 - Suppr

Suppr

超能文献

Treatment of brain metastases in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: the role of EGFR tyrosine kinase inhibitors.

作者信息

Karachaliou Niki, Rosell Rafael

机构信息

Breakthrough Cancer Research Unit, Pangaea Biotech S.L., Barcelona, Spain.

Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.

出版信息

Ann Palliat Med. 2013 Jul;2(3):114-7. doi: 10.3978/j.issn.2224-5820.2013.05.02.

DOI:10.3978/j.issn.2224-5820.2013.05.02

PMID:25842092

Abstract

摘要

相似文献

Treatment of brain metastases in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: the role of EGFR tyrosine kinase inhibitors.

Ann Palliat Med. 2013 Jul;2(3):114-7. doi: 10.3978/j.issn.2224-5820.2013.05.02.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.

Cancer Treat Rev. 2013 Dec;39(8):839-50. doi: 10.1016/j.ctrv.2013.05.001. Epub 2013 Jun 12.

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.

Clin Cancer Res. 2005 May 15;11(10):3750-7. doi: 10.1158/1078-0432.CCR-04-1981.

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.

Cancer Treat Rev. 2014 Sep;40(8):917-26. doi: 10.1016/j.ctrv.2014.06.010. Epub 2014 Jul 1.

Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.

Lung Cancer. 2013 Nov;82(2):305-12. doi: 10.1016/j.lungcan.2013.08.028. Epub 2013 Sep 8.

Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer.

Cancer Lett. 2014 Aug 28;351(1):6-12. doi: 10.1016/j.canlet.2014.04.019. Epub 2014 May 23.

Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4416s-4420s. doi: 10.1158/1078-0432.CCR-06-0555.

Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.

Clin Cancer Res. 2006 Dec 1;12(23):7117-25. doi: 10.1158/1078-0432.CCR-06-0760.

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.

J Clin Oncol. 2005 Apr 10;23(11):2556-68. doi: 10.1200/JCO.2005.07.799. Epub 2005 Mar 14.

Epidermal growth factor receptor mutations in patients with non-small cell lung cancer.

Cancer Res. 2005 Sep 1;65(17):7525-9. doi: 10.1158/0008-5472.CAN-05-1257.

引用本文的文献

EGFR first- and second-generation TKIs-there is still place for them in -mutant NSCLC patients.

Transl Cancer Res. 2019 Jan;8(Suppl 1):S23-S47. doi: 10.21037/tcr.2018.10.06.

Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non-small cell lung cancer (NSCLC) with brain metastases.

Eur J Clin Pharmacol. 2020 Oct;76(10):1427-1436. doi: 10.1007/s00228-020-02926-9. Epub 2020 Jun 11.

Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model.

J Cell Mol Med. 2018 Jun;22(6):3073-3085. doi: 10.1111/jcmm.13582. Epub 2018 Mar 24.

Diagnosis of Brain Metastases from Lung Cancer Using a Modified Electromagnetism like Mechanism Algorithm.

J Med Syst. 2016 Jan;40(1):35. doi: 10.1007/s10916-015-0367-3. Epub 2015 Nov 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验